研究等業績 - その他 - 奥田 佑道
-
気道上皮細胞からのサイトカイン産生,粘液産生におけるPhosphoinositide 3-kinase γの関わり
竹田正秀, 佐藤一洋, 植木重治, 丹典子, 泉谷有可, 熊谷奈保, 坂本祥, 須藤和久, 長谷川幸保, 浅野真理子, 奥田佑道, 佐野正明, 中山勝敏
日本呼吸器学会誌(Web) 8 2019年
-
胸郭形成術後の呼吸機能障害に対しNPPVを長期使用した高齢患者の1例
奥田佑道, 佐藤一洋, 浅野真理子, 泉谷有可, 坂本祥, 須藤和久, 竹田正秀, 佐野正明, 大田秀隆, 中山勝敏
日本老年医学会雑誌 56 ( 4 ) 2019年
-
Validity of ultrasound lungcomets for assessment of the severity of interstitial pneumonia
Asano M.
Journal of Ultrasound in Medicine ( Journal of Ultrasound in Medicine ) 37 ( 6 ) 1523 - 1531 2018年06月
OBJECTIVES: Ultrasound (US) lung comets are often observed in patients with interstitial lung disease or congestive heart failure, but few studies have explored the clinical importance of US lung comets in patients with the former condition. We explored whether the US lung comet number could be used to assess the severity of interstitial pneumonia. METHODS: Forty stable patients with interstitial pneumonia were examined. Lung comets evident on transthoracic US imaging in 12 selected regions of the posterior chest wall were analyzed. We defined lung comets accompanied by thickened and irregular pleural lines as interstitial US lung comets; these predominated in patients with interstitial pneumonia. The total number of interstitial US lung comets was correlated with the data from chest high-resolution computed tomography, pulmonary function tests, serologic tests, and the 6-minute walk test. RESULTS: The 40 patients included 16 with idiopathic pulmonary fibrosis and 24 with nonspecific interstitial pneumonia. Thirty-four patients had interstitial US lung comets, which were more common in the lower than the upper lung area. Good correlations were evident between the lung comet number and the extent of the reticular pattern on chest high-resolution computed tomography (r = 0.710; P < .01), predicted forced vital capacity (r = -0.614; P < .01), and lung diffusion capacity for carbon monoxide (r = -0.577; P < .01). Notably, the lung comet number had a strong negative correlation with the percutaneous oxygen saturation level after the 6-minute walk test (r = -0.751; P < .01). CONCLUSIONS: The number of interstitial US lung comets evident on transthoracic US imaging may be a valuable marker of disease severity in patients with interstitial pneumonia.
-
びまん性の肺動静脈奇形に対し,経カテーテルコイル塞栓術を施行した4症例
奥田佑道, 佐藤一洋, 坂本祥, 須藤和久, 長谷川幸保, 浅野真理子, 竹田正秀, 飯野健二, 佐野正明, 塩谷隆信, 橋本学, 渡邊博之
秋田医学 44 ( 3/4 ) 2018年
-
中枢神経病変により多彩な症状をきたしたサルコイドーシスの一例
浅野真理子, 佐藤一洋, 竹田正秀, 奥田佑道, 須藤和久, 長谷川幸保, 坂本祥, 佐野正明, 渡邊博之
秋田医学 44 ( 3/4 ) 2018年
-
自己免疫性好中球減少症を合併したIgG4関連疾患の一例
坂本祥, 佐藤一洋, 熊谷奈保, 須藤和久, 浅野真理子, 奥田佑道, 竹田正秀, 佐野正明, 飯野健二, 渡邊博之, 塩谷隆信
日本サルコイドーシス/肉芽腫性疾患学会雑誌 38 ( 1-2 ) 2018年
-
遺伝性出血性末梢血管拡張症(HHT)患者における頭部MRI:SWI(Susceptibility-Weighted Imaging)を含めた検討
大谷隆浩, 高橋聡, 松田雅純, 浅野友之, 大高葵, 橋本学, 奥田佑道, 佐藤一洋, 佐野正明, 塩谷隆信
Japanese Journal of Radiology 36 ( Supplement ) 2018年
-
Yokota H.
Clinical Lung Cancer ( Clinical Lung Cancer ) 18 ( 6 ) e433 - e439 2017年11月
INTRODUCTION: In this study, we investigated the degree of drug interactions between gefitinib and gastric acid suppressants (ie, histamine 2-receptor antagonists [H2RAs] or proton pump inhibitors [PPIs]) with a clinical standard dose in Japanese patients with non-small-cell lung cancer. METHODS: Retrospectively, 47 patients were divided into 3 groups: gefitinib therapy with a PPI (15 patients) or an H2RA (8 patients) or gefitinib therapy alone (24 patients). On day 15 after beginning gefitinib therapy (administration at 08:00) with or without H2RA (administration twice daily at 08:00 and 18:30) or PPI (administration once daily at 08:00 or 18:30), whole blood samples were collected just prior to and at 1, 2, 4, 6, 8, 12, and 24 hours after administration. RESULTS: The total area under the observed plasma concentration-time curve (AUC0-24) and the maximum and trough plasma concentrations of gefitinib with the PPI were significantly lower than those without the PPI. The AUC0-24 of gefitinib with PPI administration in either the morning or evening were significantly lower than those without PPI administration (P = .015 and .049, respectively); however, there were no significant differences in gefitinib AUC0-24 between patients taking PPI in the morning and evening. No significant differences were observed in gefitinib exposure among the 3 CYP2C19 genotypes. The AUC0-24 of gefitinib with H2RA tended to be lower than that without H2RA. CONCLUSION: If the plasma concentrations of gefitinib cannot be monitored, the combination of gefitinib and PPI should be avoided, and an H2RA should also be used carefully.
-
Sudo K.
Anticancer Research ( Anticancer Research ) 37 ( 10 ) 5565 - 5571 2017年10月
-
Okuda Y.
Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology ) 79 ( 5 ) 1013 - 1020 2017年05月
PURPOSE: The relationship between the pharmacokinetics and effects of gefitinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is unknown. In this study, we examined the correlation between gefitinib plasma concentration and progression-free survival (PFS) in patients with two common types of EGFR mutations: a deletion in exon 19 and point mutations in exon 21 L858R. METHODS: The retrospective analysis examined 40 patients who were administered 250 mg of gefitinib daily. All patients were diagnosed with and treated for advanced non-small cell lung carcinoma with sensitive EGFR mutations between January 2011 and November 2013 at Akita University Hospital, Akita, Japan. The 40 patients were divided into four groups by trough plasma concentration (high or low) and mutation type (exon 19 deletions or exon 21 L858R point mutations). PFS, response rate, and toxic effects were analyzed in all four groups. RESULTS: After excluding 5 patients, the remaining 35 were successfully analyzed. For the patients with exon 19 deletions, there was no significant difference in PFS between the high and low plasma concentration groups (median survival: 12.0 vs. 17.0 months, P = 0.9548). In contrast, the PFS was significantly shorter for patients with exon 21 point mutations and low vs. high concentrations of gefitinib (median survival: 8.0 vs. 16.0 months, P < 0.05). CONCLUSIONS: The results suggest that low gefitinib plasma concentrations in patients with exon 21 L858R point mutations may be associated with shorter PFS in NSCLC patients.
-
呼吸不全に関する調査研究 日本における肺動静脈奇形の遺伝性出血性末梢血管拡張症(オスラー病)の合併の有無による比較
塩谷隆信, 佐竹將宏, 上村佐知子, 岩倉正浩, 浅野真理子, 奥田佑道, 守田亮, 三浦肇, 小高英達, 佐藤一洋, 佐野正明, 伊藤宏
呼吸不全に関する調査研究 平成28年度 総括研究報告書(Web) 2017年
-
胸壁浸潤した肺結核の1例
竹田正秀, 佐藤一洋, 奥田佑道, 浅野真理子, 坂本祥, 須藤和久, 長谷川幸保, 飯野健二, 佐野正明, 渡邊博之, 伊藤宏, 塩谷隆信
結核 92 ( 5 ) 2017年